List of Excipients in Branded Drug CLOBAZAM

Generic Drugs Containing CLOBAZAM

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceuticals Corp	clobazam	0054-0526	LACTOSE MONOHYDRATE
West-Ward Pharmaceuticals Corp	clobazam	0054-0526	MAGNESIUM STEARATE
West-Ward Pharmaceuticals Corp	clobazam	0054-0526	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in CLOBAZAM?

# Of NDCs	Excipient
3	ANHYDROUS CITRIC ACID
1	ANHYDROUS LACTOSE
1	BENZOIC ACID

Clobazam Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Clobazam is a small-molecule benzodiazepine marketed in the United States for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients age 2 years and older. Its commercial opportunity is concentrated in pediatric oral delivery, dosing flexibility, taste masking, administration convenience, and differentiated formulations rather than in new chemical-entity protection. The main products are Onfi tablets and oral suspension, Sympazan oral film, and generic clobazam tablets and suspension. [1][2][3]

The strongest excipient opportunities are pediatric-friendly liquids, orally disintegrating or multiparticulate systems, alcohol-free and sugar-free suspensions, taste-masked products, and unit-dose packaging. Clobazam is not a biologic, so biosimilar pathways do not apply. Generic and 505(b)(2) competition remain the principal commercial risks.

What excipient strategy best fits clobazam products?

The most commercially relevant excipient strategy is to optimize palatability, dose uniformity, physical stability, and ease of administration without materially changing clobazam exposure.

Clobazam has a high-value pediatric use case. Patients with Lennox-Gastaut syndrome can require chronic treatment, often with multiple antiepileptic drugs. Caregivers need products that support accurate dosing, administration through feeding systems, and adherence in patients who cannot reliably swallow tablets.

Product objective	Excipient or formulation function	Commercial value
Pediatric palatability	Sweeteners, flavors, bitterness suppressants, polymeric taste barriers	Improves adherence and repeat use
Dose uniformity	Suspending agents, wetting agents, particle-size control	Reduces dosing variability
Physical stability	Buffers, preservatives, chelators, viscosity modifiers	Extends shelf life and supports multi-dose packaging
Tablet disintegration	Superdisintegrants and optimized compression	Enables smaller or faster-dispersing tablets
Oral film performance	Film-forming polymers, plasticizers, surfactants, sweeteners	Supports water-free administration
Feeding-tube use	Controlled viscosity, low sedimentation, low adsorption	Expands use in medically complex patients
Packaging stability	Moisture barriers, light protection, unit-dose systems	Protects potency and reduces dosing errors

Excipients should be selected against the intended regulatory pathway. A conventional generic should minimize formulation differences from the reference product where possible. A 505(b)(2) product can justify a more differentiated delivery system if the clinical or adherence benefit is supported.

What are the current clobazam dosage forms and excipient platforms?

The principal U.S. reference products use tablets, an oral suspension, and an oral film.

Onfi tablets

Onfi tablets are available in 10 mg and 20 mg strengths. The product is intended for oral administration and can be administered whole, divided, or crushed according to the prescribing information. The inactive ingredients identified in the product labeling include conventional tablet excipients such as lactose, starch-based materials, and lubricants. [1]

The tablet platform is difficult to differentiate through excipients alone. A generic tablet can compete on price, supply reliability, and pharmacy substitution. More defensible opportunities require a clinically meaningful feature, such as:

• rapid disintegration;
• reduced tablet size;
• improved swallowability;
• lower friability;
• unit-dose packaging;
• compatibility with a specific administration protocol.

A lactose-free or low-lactose tablet could target patients with excipient intolerance, although the commercial segment would likely be narrow unless supported by a broader formulation advantage.

Onfi oral suspension

Onfi oral suspension is supplied at 2.5 mg/mL. The formulation uses a liquid suspension platform with viscosity control, wetting, preservation, buffering, and sweetening functions. The label instructs shaking before use and provides dosing instructions based on an oral syringe. [1]

The suspension has the clearest excipient opportunity because pediatric dosing creates recurring formulation problems:

• clobazam bitterness;
• sedimentation and redispersion;
• dose withdrawal from the bottle;
• preservative tolerability;
• microbial control;
• syringe compatibility;
• administration through enteral feeding tubes;
• storage after opening.

A differentiated suspension could use a structured vehicle with lower sedimentation, improved redispersion after standing, and reduced viscosity during syringe withdrawal. The target is a formulation that remains physically stable but does not create excessive resistance in an oral syringe.

Taste masking is commercially important. A simple sweetener system may not sufficiently suppress benzodiazepine bitterness. Polymer coating of clobazam particles, ion-pairing, lipid-based barriers, or optimized flavor systems could provide stronger differentiation. The formulation must avoid delayed or incomplete release after taste masking.

Sympazan oral film

Sympazan is an oral film available in 5 mg, 10 mg, and 20 mg strengths. It is designed to dissolve in the mouth without requiring a conventional tablet or liquid dose. The product uses a film-forming polymer system with plasticizers, sweetening or flavoring components, and other excipients needed for drying, flexibility, and dose uniformity. [2]

The film platform addresses patients who have difficulty swallowing tablets and caregivers who want a portable, water-free product. Its commercial limitations include:

• manufacturing complexity;
• moisture sensitivity;
• packaging cost;
• unit-dose requirements;
• potential handling problems for patients with impaired dexterity;
• taste and mouthfeel;
• scale-up risk for dose uniformity.

A generic or follow-on oral film must demonstrate pharmaceutical equivalence or an acceptable alternative regulatory basis. Manufacturing controls are likely to be more important than the identity of any individual excipient. Film thickness, drying conditions, residual moisture, polymer grade, and content uniformity can materially affect performance.

What excipients are most valuable for pediatric clobazam?

Taste masking, dosing accuracy, and administration flexibility have the highest commercial value.

Taste masking systems

Clobazam liquid products need a coordinated taste-masking system rather than a single sweetener. Candidate approaches include:

• high-intensity sweeteners;
• polyols;
• flavors selected for bitterness suppression;
• polymer-coated drug particles;
• lipid or wax barriers;
• ion-exchange or complexation systems;
• pH adjustment where compatible with stability and tolerability.

The key development risk is rebound bitterness after swallowing. A formulation can test well during the first seconds of administration but fail after the drug disperses in saliva or reaches the oropharynx.

Suspending agents

Common suspending-agent classes include cellulose derivatives, xanthan gum, carbomers, and combinations of structured polymers. The formulation must balance sedimentation control against syringeability. Excessive viscosity may improve suspension stability while making accurate administration harder.

A commercially attractive product would show:

• rapid redispersion after defined storage intervals;
• low variability between first and last doses;
• consistent withdrawal through the supplied syringe;
• stable viscosity across temperature ranges;
• low foaming;
• compatibility with enteral tubes.

Preservatives and buffers

Multi-dose aqueous clobazam products require microbial-control strategies. Sodium benzoate, parabens, sorbates, or alternative preservation systems may be considered depending on pH, packaging, and excipient compatibility.

Pediatric development should avoid unnecessary exposure to excipients with age-specific tolerability concerns. Preservative selection also affects taste, odor, container compatibility, and regulatory acceptability.

Film-forming polymers

Oral films commonly use hydrophilic polymers such as hypromellose, pullulan, or related film-forming materials. Plasticizers control flexibility and handling. Surfactants and wetting agents can improve drug distribution but may affect mouthfeel and film drying.

For clobazam, the product target is not simply rapid dissolution. The film must deliver an accurate dose, resist cracking, maintain stability under humidity stress, and release clobazam without excessive bitterness.

What formulation patents could protect clobazam products?

The most defensible formulation claims would cover the full composition and performance profile rather than an isolated conventional excipient.

Potential claim categories include:

1. A clobazam suspension containing specified polymer concentrations, pH, preservative levels, particle-size distribution, and redispersibility limits.
2. A taste-masked clobazam particle with a defined coating material, coating weight gain, and dissolution profile.
3. An oral film with a specified clobazam loading, polymer matrix, residual-water range, disintegration time, and content-uniformity performance.
4. A formulation compatible with nasogastric or gastrostomy-tube administration.
5. A unit-dose package that protects the formulation from moisture or supports accurate pediatric dosing.
6. A manufacturing process that produces a specified particle-size distribution or film uniformity.
7. A method of administering clobazam to patients unable to swallow tablets.

Patent strength depends on measurable technical limitations. Claims directed only to a familiar sweetener, standard suspending agent, or routine concentration range are vulnerable to obviousness attacks. Claims combining excipient selection with unexpected stability, taste, bioavailability, or administration performance are more defensible.

When does clobazam lose exclusivity, and what is the generic entry risk?

The original clobazam active-ingredient patent estate is mature. U.S. generic competition already exists for clobazam tablets and oral suspension. The primary commercial protection for differentiated products is therefore formulation, manufacturing, regulatory exclusivity, branding, and distribution rather than basic molecule exclusivity. [4][5]

Protection category	Clobazam position
Active ingredient	Mature small-molecule estate
Pediatric use	Lennox-Gastaut indication is reflected in product labeling and historical regulatory exclusivity
Tablets	Generic competition established
Oral suspension	Generic competition established or commercially available depending on market and product status
Oral film	More differentiated dosage form with higher formulation and manufacturing barriers
Biosimilar risk	Not applicable
Paragraph IV risk	Relevant to any listed formulation or method patent
505(b)(2) opportunity	Potentially relevant for a new dosage form, route, excipient system, or administration advantage

The reference product for an abbreviated new drug application is generally the relevant listed drug in the FDA Orange Book. A generic applicant may pursue a Paragraph IV certification against listed patents or a Paragraph III certification for later entry. The commercial risk depends on whether the challenged patent claims cover a core product feature or a narrow formulation limitation. [4]

What is the Orange Book status of clobazam products?

The FDA Orange Book identifies approved drug products, reference listed drugs, therapeutic-equivalence information, and patent or exclusivity information for eligible products. Onfi and Sympazan should be evaluated separately because their dosage forms and regulatory histories differ. [4]

Orange Book analysis should distinguish:

• Onfi tablets;
• Onfi oral suspension;
• Sympazan oral film;
• generic clobazam tablets;
• generic clobazam oral suspension;
• active listed patents;
• use codes;
• pediatric exclusivity;
• expiration dates;
• 30-month litigation stays, where applicable.

A formulation patent listed against an oral film does not automatically block a tablet or suspension. Conversely, a method-of-use patent may affect labeling strategy even when the generic formulation itself is not covered.

Which companies are challenging or competing with clobazam products?

The competitive field includes generic pharmaceutical companies, branded product owners, and developers of alternative seizure treatments.

Generic manufacturers

Generic competition is most direct for tablets and oral suspension. Competition typically centers on:

• abbreviated new drug application approval;
• manufacturing cost;
• API sourcing;
• supply continuity;
• wholesaler access;
• substitution status;
• product availability during shortages.

A differentiated generic suspension can command a price premium only if it delivers a clear operational benefit, such as superior taste, more reliable redispersion, or improved tube administration.

Branded and specialty manufacturers

Specialty manufacturers may compete through oral film, pediatric packaging, patient-support programs, and distribution to neurology practices. The oral film category offers a higher barrier than standard tablets but also carries higher production and packaging costs.

Alternative antiseizure drugs

Clobazam competes clinically with other agents used in Lennox-Gastaut syndrome, including cannabidiol, rufinamide, lamotrigine, topiramate, valproate, and felbamate. [6] These products differ in mechanism, safety profile, dosage form, drug interactions, and reimbursement. A clobazam formulation that improves adherence can compete even without changing the active ingredient.

What FDA regulatory pathway applies to a new clobazam formulation?

A conventional tablet or suspension may qualify for an ANDA if the applicant can demonstrate pharmaceutical equivalence, bioequivalence, and conformity with applicable quality requirements.

A new oral film, taste-masked system, or materially different administration method may require a 505(b)(2) application if the product relies partly on FDA findings for an approved product but introduces changes that cannot be addressed through a standard ANDA. [7]

The pathway depends on:

• dosage form;
• route of administration;
• strength;
• inactive ingredients;
• release characteristics;
• bioequivalence risk;
• clinical labeling;
• reliance on the reference product;
• whether a new indication or administration method is proposed.

For pediatric liquids, FDA scrutiny will focus on dose uniformity, microbiological quality, preservative effectiveness, extractables and leachables, container-closure integrity, and age-appropriate administration. For oral films, the agency will focus on content uniformity, residual solvents, residual moisture, mechanical properties, dissolution, and stability.

How strong is the patent estate for clobazam?

The clobazam patent estate is stronger for differentiated delivery systems than for the active molecule.

Asset type	Relative protection strength	Reason
Basic clobazam composition	Low	Mature molecule and established generic competition
Conventional tablet	Low to moderate	Limited room for non-obvious excipient differentiation
Pediatric suspension	Moderate	Stability, taste masking, and tube-use claims can create barriers
Oral film	Moderate to strong	Manufacturing, moisture control, and content-uniformity barriers
Taste-masked particles	Moderate	Stronger if supported by unexpected sensory or release data
Method of administration	Moderate	Depends on novelty and enforceable patient-selection limitations
Manufacturing process	Moderate	Can delay competitors if difficult to design around
Packaging system	Low to moderate	More useful as a supporting patent than a standalone moat

The best patent strategy uses layered protection: composition claims, performance claims, process claims, packaging claims, and method-of-use claims. Trade secrets are important for coating parameters, mixing order, drying conditions, and sensory optimization because these details may be difficult to identify from the marketed product.

What licensing deals and commercial partnerships are relevant?

Clobazam licensing opportunities are more likely to involve formulation technology, pediatric delivery platforms, API supply, contract manufacturing, or regional commercialization rights than a license to the underlying molecule.

Potential transaction structures include:

• regional rights for an oral film or suspension;
• co-development of a pediatric formulation;
• licensing of taste-masking technology;
• exclusive supply of coated clobazam particles;
• contract manufacturing with technology transfer;
• royalty-bearing rights under formulation patents;
• commercialization partnerships with specialty neurology distributors.

The value of a transaction will depend on whether the product can obtain substitution, achieve differentiated reimbursement, and maintain reliable supply. A formulation that is clinically convenient but not substitutable may require a stronger commercial model involving prescriber adoption and caregiver education.

What revenue exposure exists for clobazam products?

Revenue exposure is concentrated in chronic Lennox-Gastaut treatment and is sensitive to generic substitution. Tablets face the greatest price erosion because manufacturing is relatively conventional. Oral suspension and oral film products can preserve higher gross margins if they offer clear administration benefits and maintain limited competition.

The principal revenue drivers are:

• number of treated Lennox-Gastaut patients;
• persistence on therapy;
• pediatric dosing requirements;
• branded versus generic substitution;
• reimbursement tier placement;
• supply reliability;
• dosage-form preference;
• competition from cannabidiol and other antiseizure medicines;
• ability to obtain favorable pharmacy and specialty-distribution access.

The most attractive commercial segment is a pediatric product that reduces administration burden without requiring a complex clinical switching program.

What generic launch scenarios exist for clobazam?

Low-cost tablet entry

This scenario produces the fastest price erosion and offers limited differentiation. The product competes on approval timing, supply, and contract pricing.

Generic oral suspension entry

This scenario creates greater manufacturing and quality-control demands. A reliable suspension can gain market share from tablets in pediatric patients, but taste and redispersion performance will determine retention.

Differentiated 505(b)(2) oral film

This scenario has higher development costs and greater regulatory complexity. It can support premium pricing if the film improves administration, avoids water, and performs reliably in patients with dysphagia.

Taste-masked pediatric product

This scenario targets adherence and caregiver acceptance. Its value depends on sensory data, not only dissolution or bioequivalence.

What manufacturing and IP barriers affect clobazam formulation opportunities?

The largest barriers are process reproducibility and product-performance consistency.

For suspensions, critical manufacturing variables include API particle size, wetting sequence, shear rate, polymer hydration, pH adjustment, deaeration, filling, and bottle-syringe interaction.

For oral films, key variables include solution viscosity, drug dispersion, casting thickness, drying profile, residual moisture, film-cutting accuracy, and moisture-barrier packaging.

API sourcing is less likely to provide a durable moat because clobazam is an established compound with multiple potential suppliers. The more defensible barriers are proprietary particle engineering, taste-masking processes, film manufacturing know-how, validated container-closure systems, and patent claims tied to measurable product performance.

Key Takeaways

• Clobazam’s active-ingredient exclusivity is mature, and generic competition is established.
• The best commercial opportunities are pediatric suspensions, taste-masked products, oral films, and feeding-tube-compatible formulations.
• Excipients should be selected for palatability, redispersion, syringeability, stability, and dose uniformity.
• Conventional excipient substitutions are unlikely to create strong patent protection without unexpected performance data.
• Oral film and engineered suspension technologies offer stronger formulation and manufacturing barriers than standard tablets.
• Biosimilar risk does not apply because clobazam is a small molecule.
• ANDA pathways are most suitable for conventional tablets and suspensions; a 505(b)(2) pathway may be relevant for materially differentiated dosage forms.
• Commercial value depends on pediatric adherence, substitution status, reimbursement, and supply reliability.
• A layered IP strategy should combine formulation, process, packaging, and method-of-use claims.

FAQs

Can clobazam be formulated without sugar?

Yes. A sugar-free suspension can use high-intensity sweeteners, polyols, flavors, and taste-masking technologies. The formulation must still demonstrate acceptable palatability, stability, preservative performance, and dose uniformity.

Is clobazam suitable for an orally disintegrating tablet?

Yes, but the formulation must address clobazam’s taste, dose loading, mechanical strength, disintegration time, and moisture sensitivity. Taste masking is likely to be the main development issue.

Can a clobazam suspension be administered through a feeding tube?

Potentially. The formulation must be evaluated for viscosity, sedimentation, tube adsorption, dose recovery, clogging, and compatibility with the specific tube materials and sizes used in clinical practice.

What is the main weakness of a clobazam oral film business?

The main weakness is manufacturing and packaging cost. Oral films require tight control of content uniformity, residual moisture, mechanical properties, and dose cutting, which can reduce margins compared with conventional tablets.

Are excipient patents alone sufficient to block a generic clobazam product?

Usually not. A patent directed only to a routine excipient or conventional concentration may be vulnerable. Stronger protection generally requires a defined formulation combination linked to unexpected stability, taste, bioavailability, dissolution, or administration performance.

References

1. U.S. Food and Drug Administration. (2023). Onfi (clobazam) tablets and oral suspension: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Sympazan (clobazam) oral film: Prescribing information. FDA.

3. National Library of Medicine. (2024). Clobazam drug labeling and inactive ingredient information. DailyMed.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

5. U.S. Food and Drug Administration. (2024). Generic drugs: ANDA approvals and patent certifications. FDA.

6. U.S. Food and Drug Administration. (2023). Treatment of seizures associated with Lennox-Gastaut syndrome: Approved drug labeling. FDA.

7. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). FDA.